ImmunoLogik GmbH

📍 Berlin, Germany🗓 Founded 2012👥 2 employees💰 Last funded Jun 2017
Biotechnology Research🌐 immunologik.de
Website LinkedIn
OUR SOLUTION APPROACH AGAINST SARS-CoV-2 IML-206 as a broad-spectrum antiviral drug for the treatment of patients infected with SARS-CoV-2 or other (future) coronaviruses. Unlike many other developments, the innovative substance IML-206 blocks specific cellular structures in humans, which are very likely indispensable for the replication of a broad range of coronavirus variants. OUR SOLUTION APPROACH AGAINST HIV RESISTANCES IML-106 for the efficient and essential treatment of patients who have exploited all available means of the modern therapy, and who would die due to the unavoidable outbreak of AIDS. The lead candidate targets directly the components of the host cell, which are essential for the replication of HIV. The goal is to significantly reduce the risk of resistant virus variations.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2012
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
1
Frequently asked questions
Who invested in ImmunoLogik GmbH?
ImmunoLogik GmbH has 1 investors on record on gritt.io, 1 mid-stage.
When did ImmunoLogik GmbH last raise funding?
The most recent investment in ImmunoLogik GmbH recorded on gritt.io was in June 2017.
When was ImmunoLogik GmbH founded?
ImmunoLogik GmbH was founded in 2012.
What industry is ImmunoLogik GmbH in?
ImmunoLogik GmbH operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is ImmunoLogik GmbH based?
ImmunoLogik GmbH is headquartered in Berlin, Germany.